Hormone Management for Transgender Females

Core Components of Feminizing Hormone Therapy

Estradiol is the cornerstone of feminizing hormone therapy, available in oral, transdermal, or injectable forms, as recommended by medical guidelines 1, 2
Estrogen therapy induces changes in body composition, breast growth, skin softening, and decreased body/facial hair, with a 3.0-5.5% reduction in lean body mass and significant decreases in hemoglobin levels 1, 3, 4, 5
The American College of Physicians suggests that physical changes from estradiol therapy include decreased lean body mass and hemoglobin levels 1, 3

Anti-Androgen Options

Anti-androgens are typically added to enable lower doses of estrogen while achieving adequate testosterone suppression, with common options including spironolactone, cyproterone acetate, GnRH agonists, bicalutamide, and finasteride 1, 3, 2, 4, 6
The Endocrine Society recommends that spironolactone is the most commonly used anti-androgen in many countries 2, 4

Monitoring and Dosing Considerations

Target testosterone levels should be <50 ng/dL, with target estradiol levels in the cisgender female reference range, as suggested by the American Association of Clinical Endocrinologists 1, 3, 4, 5
The World Professional Association for Transgender Health recommends regular monitoring of hormone levels, including estradiol and testosterone, every 3-6 months during the first year, then annually if stable 2, 4

Clinical Effects and Timeline

Breast development is a key outcome for many transgender women, with studies showing variable results, including 1% with cup size less than A, 9% with A cup, 16% with B cup, and 1% with E cup, as reported by the American Medical Association 1, 3
The American College of Cardiology notes that muscle changes include a 5% decrease in thigh muscle volume and a 4% decrease in quadriceps cross-sectional area, despite these changes, transgender women may retain greater muscle cross-sectional area than cisgender women 1, 3

Cardiovascular Risk Considerations

Transgender women have an increased risk of venous thromboembolism compared to cisgender men and women, with an elevated risk of ischemic stroke and myocardial infarction, as reported by the American Heart Association 5, 6
The American College of Physicians recommends that the thrombosis risk persists despite changes in estradiol dosing and preparations over time, requiring individualized risk assessment 5, 6

Monitoring Algorithm

Baseline assessment should include complete blood count, liver function, lipid profile, glucose, and baseline hormone levels, with initial follow-up at 3 months to check estradiol and testosterone levels, as suggested by the Endocrine Society 2, 4
The World Professional Association for Transgender Health recommends dose adjustments based on hormone levels and clinical response, with ongoing monitoring every 3-6 months during the first year, then annually if stable 2, 4

Hormone Regulation and Therapy in Male-to-Female Gender Transition

Introduction to Hormone Therapy

GnRH analogues (puberty blockers) directly suppress FSH and LH production by acting on the hypothalatic-pituitary axis, effectively halting testosterone production at its source, as recommended by the American College of Obstetricians and Gynecologists 7, 8
Bicalutamide and finasteride act peripherally as androgen receptor antagonists without necessarily lowering testosterone concentrations, according to the Endocrine Society 7

Clinical Effects and Monitoring

Feminizing hormone therapy induces physical changes, including decreased muscle mass and changes in body composition, such as a 3.0-5.5% reduction in lean body mass and increases in total body fat, as reported by the Annual Review of Medicine 9
Transgender women have an increased risk of venous thromboembolism compared to cisgender individuals, and ethinyl estradiol may increase VTE risk more than other estrogen formulations, as noted by the American Heart Association 9

Hormone Therapy for Gender Confirmation

Medication Mechanisms and Effects

Spironolactone functions as an aldosterone receptor antagonist with potent anti-androgen activity by decreasing testosterone production and competitively inhibiting binding of testosterone and dihydrotestosterone to androgen receptors, according to the American Academy of Dermatology 10
Spironolactone may also inhibit 5-alpha-reductase and increase steroid hormone-binding globulin, as reported by the American Academy of Dermatology 10
The starting dose of 25mg spironolactone daily is very conservative; typical doses range from 50-200mg daily, as stated by the American Academy of Dermatology 11, 10

Medical Monitoring and Side Effects

At the starting dose of 25mg spironolactone, routine potassium monitoring is unnecessary in young healthy individuals, according to the American Academy of Dermatology 11, 12
Only 0.75% of young women taking spironolactone 50-200mg daily for acne had potassium levels exceeding 5.0 mmol/L, as reported by the American Academy of Dermatology 13, 12
Potassium monitoring should be considered if dose increases significantly or if taking ACE inhibitors, ARBs, NSAIDs, or digoxin, as recommended by the American Academy of Dermatology 13
Diuresis (29%), menstrual irregularities (22%), breast tenderness (17%), breast enlargement, fatigue, headache, and dizziness are common side effects of spironolactone, according to the American Academy of Dermatology 13, 12

Medication Interactions

Ziprasidone, Wellbutrin (bupropion), buspirone, hydroxyzine, and Focalin (dexmethylphenidate) have no documented interactions with estradiol or spironolactone, as stated by the American Academy of Dermatology 13

Estrogen Dosing Considerations

Introduction to Estrogen Therapy

The American College of Physicians suggests that trans females typically receive higher doses of estrogen than cis females, as the goal is to achieve adult female estradiol levels while simultaneously suppressing endogenous testosterone production—a requirement not present in cis females who already have physiologic estrogen and low testosterone 14, 15

Key Dosing Differences

The Endocrine Society recommends that trans females aim for target estradiol levels within the adult female reference range, and dual therapeutic goals of achieving feminization and suppressing testosterone to <50 ng/dL 14, 15
The World Professional Association for Transgender Health suggests that typical regimens for trans females include estrogen combined with adjunct antiandrogens to enable lower estrogen doses while achieving testosterone suppression 14, 15
The American Heart Association notes that trans women have a higher risk of venous thromboembolism (VTE) than cis women on either oral contraceptives or hormone replacement therapy (HRT) 16

Cardiovascular Risk Management

The American College of Cardiology states that trans women have an elevated risk of ischemic stroke and myocardial infarction compared to cis women, independent of HRT formulation 16
The American Society of Anesthesiologists recommends that thromboprophylaxis strategies are essential, particularly peri-operatively, and that the decision to continue or temporarily cease estradiol therapy before surgery requires individualized thrombosis risk assessment 16

Critical Dosing Considerations

The European Society of Cardiology notes that trans women have a three-fold increase in cardiovascular death and elevated VTE risk compared to cis women, which is dose-dependent 17

Laboratory Monitoring for Trans Females on Estradiol

Baseline and Ongoing Laboratory Assessment

After 12 months on estradiol, creatinine interpretation should use female reference ranges, as values shift toward the affirmed gender, according to the American Cancer Society 18, 19, 20
The American Cancer Society recommends using female reference ranges for most parameters, including creatinine, hemoglobin, and liver enzymes, after 12 months on estradiol 18, 19, 20
Consider cystatin C for kidney function assessment, as it is less dependent on muscle mass and may provide more accurate results, as suggested by the American Cancer Society 21
Liver enzymes shift toward female reference ranges after 12 months of therapy, and routine monitoring may not be necessary, but baseline assessment helps establish individual patterns, according to the American Cancer Society 18, 19
After 12 months on estradiol, interpret hemoglobin using female reference ranges, as recommended by the American Cancer Society 18
The American Cancer Society suggests that HbA1c reference ranges are not sex-specific, and baseline and periodic assessment of glucose/HbA1c is recommended 19, 20

Special Considerations for Laboratory Interpretation

The American Cancer Society recommends interpreting lab values in context of type, dose, and duration of therapy for individuals on estradiol for less than 12 months, as values may change over time 18, 19
If estradiol is stopped for 3 months or more, revert to male reference ranges, as values return to baseline within 3 months, according to the American Cancer Society 18, 19, 20
Avoid using male reference ranges after 12 months of therapy, as most lab values shift to female ranges, and continued use of male references may lead to misinterpretation, as warned by the American Cancer Society 18, 19, 20
Ignoring the timing of labs relative to therapy duration can lead to misinterpretation, as laboratory values are dynamic and depend on whether the individual is receiving estradiol and for how long, according to the American Cancer Society 18

Intermittent Estradiol Therapy for Minimal Feminization

Protocol for Intermittent Dosing

Administer estradiol 0.5 mg daily for a period of 3–6 months, then discontinue estradiol for an equal interval of 3–6 months before restarting the cycle. 22

Rationale and Expected Benefits

The intermittent schedule is modeled on intermittent androgen‑deprivation therapy used in prostate cancer, which has been shown to improve quality‑of‑life metrics during off‑treatment periods. 22